Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1880

Sort by

Sort Order Select

Journal Articles

Hyperstable SGK1 steps out of AKT’s shadow

Franziska Gehringer, Alexey Ushmorov

Blood (2021) 138 (11): 917–918.

https://doi.org/10.1182/blood.2021012518

Published: 2021

Journal Articles

SGK1 mutations in DLBCL generate hyperstable protein neoisoforms that promote AKT independence

Jie Gao, Eirini Sidiropoulou, Ieuan Walker, Joanna A. Krupka, Karol Mizielinski, Zelvera Usheva, Shamith A. Samarajiwa, Daniel J. Hodson

Blood (2021) 138 (11): 959–964.

https://doi.org/10.1182/blood.2020010432

Published: 2021

Includes: Supplemental data

Journal Articles

Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing

Blood (2020) 136 (5): 572–584.

https://doi.org/10.1182/blood.2019002385

Published: 2020

Includes: Supplemental data

Journal Articles

Aberrant RNA Splicing Contributes to the Pathogenesis of EVI-Rearranged Myeloid Leukemias

Daichi Inoue, MD PhD, Stanley C Lee, PhD, Akihide Yoshimi, MD PhD, Justin Taylor, MD, Lillian E Bitner, BSc, Atsushi Tanaka, MD, Yasutaka Hayashi, MD PhD, Hana Cho, MSc, Chie Fukui, Ruth Saganty, Alexander V Penson, PhD, Omar Abdel-Wahab, MD

Blood (2019) 134 (Supplement_1): 917.

https://doi.org/10.1182/blood-2019-124722

Published: 2019

Journal Articles

Prediction of Patients at Risk of CD19 Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia

Pablo Domizi, PhD, Astraea Jager, BS, Jolanda Sarno, PhD, Charles G. Mullighan, MBBS, MD, Stephan Grupp, MD PhD, Elena Sotillo, PhD, David M. Barrett, Kara L. Davis, DO

Blood (2019) 134 (Supplement_1): 749.

https://doi.org/10.1182/blood-2019-128883

Published: 2019

Journal Articles

The Biological and Clinical Implications of the Alternative Splicing Landscape of 1,258 Myeloid Neoplasm Cases

Courtney E Hershberger, BS, Devlin C Moyer, BS, Wencke Walter, PhD, Stephan Hutter, PhD, Claudia Haferlach, MD, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD, Richard A Padgett, PhD

Blood (2019) 134 (Supplement_1): 769.

https://doi.org/10.1182/blood-2019-128278

Published: 2019

Journal Articles

CD162 Is a Key E-Selectin Receptor Promoting Acute Myeloid Leukemia Chemo-Resistance in the Bone Marrow Niche

Johanna D Erbani, Joshua Tay, PhD, Valerie Barbier, Masters, Jean-Pierre Levesque, PhD, John L. Magnani, PhD, Ingrid G Winkler, PhD

Blood (2019) 134 (Supplement_1): 907.

https://doi.org/10.1182/blood-2019-132233

Published: 2019

Journal Articles

The Splicing Factor RBM17 Supports Leukemia Stem Cell Self-Renewal

Lina Liu, Ana Vujovic, Joshua Xu, Kristin Hope, PhD, Yu Lu, PhD

Blood (2019) 134 (Supplement_1): 1238.

https://doi.org/10.1182/blood-2019-126287

Published: 2019

Journal Articles

Bleeding in Mild Hemophilia A Due to a Splice-Site F8 Mutation May be Fully Abrogated By Prothrombotic Gene Variants

Peter H. Cygan, MD, Sarah E. Arnold-Croop, MS, Elizabeth A. Weidman, BS, Fang Chen, PhD, Dajiang J. Liu, PhD, M. Elaine Eyster, MD, Laura Carrel, PhD

Blood (2019) 134 (Supplement_1): 1125.

https://doi.org/10.1182/blood-2019-126026

Published: 2019

Journal Articles

Novel CD33 Antibodies Unravel Localization, Biology, and Therapeutic Implications of CD33 Isoforms

Mohammed Gbadamosi, BS, Tiffany A. Hylkema, BS, Soheil Meshinchi, MD PhD, Jatinder K Lamba, M.Sc., PhD

Blood (2019) 134 (Supplement_1): 908.

https://doi.org/10.1182/blood-2019-122596

Published: 2019

Journal Articles

Discovery of Novel IL3RA (CD123) Isoforms By Long Read Transcriptomics, Heterogeneous Expression Among AML Patient Cohorts and the Implications for Anti-CD123 Therapeutics

Jason G Underwood, PhD BA, Jenny L. Smith, MSc, MD, Lindsey F. Call, B.A., Elizabeth Tseng, PhD, Tiffany A. Hylkema, BS, Rhonda E. Ries, MA, Amanda R. Leonti, MS, Jason E. Farrar, MD, Timothy Junius Triche, Jr., PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 4658.

https://doi.org/10.1182/blood-2019-131508

Published: 2019

Journal Articles

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Evangelos Terpos, MD PhD, Eftathios Kastritis, Evdoxia Hatjiharissi, Eirini Katodritou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Evgenia Verrou, MD, Maria Gavriatopoulou, MD, Alexandros Leonidakis, PhD, Ioannis Ntanasis-Stathopoulos, MD, Sosana Delimpasi, MD, Marie-Christine Kyrtsonis, MD PhD, Maria Papaioannou, Argiris Symeonidis, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1837.

https://doi.org/10.1182/blood-2019-124638

Published: 2019

Journal Articles

Plasma EDA Fibronectin in Primary Myelofibrosis Correlates with Bone Marrow Fibrosis and Predicts Splenomegaly

Alessandro Malara, PhD, Cristian Gruppi, PhD, Margherita Massa, Vittorio Rosti, MD, Giovanni Barosi, Alessandra Balduini, MD

Blood (2019) 134 (Supplement_1): 1688.

https://doi.org/10.1182/blood-2019-130735

Published: 2019

Journal Articles

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

Blood (2019) 134 (Supplement_1): 1638.

https://doi.org/10.1182/blood-2019-127951

Published: 2019

Journal Articles

Histone 1 Mutations Drive Lymphomagenesis By Inducing Primitive Stem Cell Functions and Epigenetic Instructions through Profound 3D Re-Organization of the B-Cell Genome

Nevin Yusufova, Matthew R Teater, PhD, Alexey Soshnev, Andreas Kloetgen, Adewola Osunsade, Joseph Conway, Ashley Doane, Arthur Skoultchi, Aristotelis Tsirigos, PhD, Yael David, C. David Allis, PhD, Ethel Cesarman, MD PhD, Ari Melnick, MD

Blood (2019) 134 (Supplement_1): 23.

https://doi.org/10.1182/blood-2019-127774

Published: 2019

Journal Articles

The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia

Elizabeth M. Muhowski, Amy M. Lehman, M.A.S, Sean D. Reiff, PhD, Janani Ravikrishnan, Rose Mantel, Shrilekha Misra, Michael Niesman, PhD, Kai Zhang, MD, James S. Blachly, MD, Deepa Sampath, PhD, John C. Byrd, MD, Jennifer Woyach, MD

Blood (2019) 134 (Supplement_1): 2077.

https://doi.org/10.1182/blood-2019-128871

Published: 2019

Journal Articles

Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs)

Paola Guglielmelli, MD PhD, Niccolò Bartalucci, PhDBSc, Elisa Contini, PhD, Giada Rotunno, PhD, Annalisa Pacilli, PhD, Simone Romagnoli, BSc, Lara Mannelli, MD, Francesco Mannelli, MD, Giacomo Coltro, MD, Alessandro Pancrazzi, PhD, Valentina Ariu, BSci, Sara Fiaccabrino, Roberto Semeraro, Alberto Magi, PhD, Carmela Mannarelli, PhD, Francesca Gesullo, BSci, Chiara Paoli, PhD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 2968.

https://doi.org/10.1182/blood-2019-129094

Published: 2019

Journal Articles

Class I PI3K Is Required for HSC Differentiation

Kristina Ames, PhD, Imit Kaur, PhD, Meng Tong, Shayda Hemmati, PhD, Ellen Tein, Shira Glushakow-Smith, Lindsay Gurska, Kira Gritsman, MD PhD

Blood (2019) 134 (Supplement_1): 2461.

https://doi.org/10.1182/blood-2019-123823

Published: 2019

Journal Articles

Altered Iron Parameters and Hepcidin Levels in a General Population: Lessons from the CHRIS Study

Fabiana Busti, MD PhD, Annalisa Castagna, B.S., PhD, Giacomo Marchi, MD, Oliviero Olivieri, MD, Peter Pramstaller, MD, Domenico Girelli, MD, PhD

Blood (2019) 134 (Supplement_1): 2239.

https://doi.org/10.1182/blood-2019-127098

Published: 2019

Journal Articles

PI3Kδ Inhibition Enhances Sensitivity of Primary High-Risk Childhood B-Cell Acute Lymphoblastic Leukemia Cells to Glucocorticoid Chemotherapy

Jessica A.O. Zimmerman, MD, Mimi Fang, Arunkumar Modi, MBBS, MPH, Adam Dupuy, PhD, Sarah K. Tasian, MD, Miles A. Pufall, PhD

Blood (2019) 134 (Supplement_1): 2572.

https://doi.org/10.1182/blood-2019-129205

Published: 2019

NARROW

Hyperstable SGK1 steps out of AKT’s shadow

SGK1 mutations in DLBCL generate hyperstable protein neoisoforms that promote AKT independence

Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing

Aberrant RNA Splicing Contributes to the Pathogenesis of EVI-Rearranged Myeloid Leukemias

Prediction of Patients at Risk of CD19 Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia

The Biological and Clinical Implications of the Alternative Splicing Landscape of 1,258 Myeloid Neoplasm Cases

CD162 Is a Key E-Selectin Receptor Promoting Acute Myeloid Leukemia Chemo-Resistance in the Bone Marrow Niche

The Splicing Factor RBM17 Supports Leukemia Stem Cell Self-Renewal

Bleeding in Mild Hemophilia A Due to a Splice-Site F8 Mutation May be Fully Abrogated By Prothrombotic Gene Variants

Novel CD33 Antibodies Unravel Localization, Biology, and Therapeutic Implications of CD33 Isoforms

Discovery of Novel IL3RA (CD123) Isoforms By Long Read Transcriptomics, Heterogeneous Expression Among AML Patient Cohorts and the Implications for Anti-CD123 Therapeutics

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Plasma EDA Fibronectin in Primary Myelofibrosis Correlates with Bone Marrow Fibrosis and Predicts Splenomegaly

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

Histone 1 Mutations Drive Lymphomagenesis By Inducing Primitive Stem Cell Functions and Epigenetic Instructions through Profound 3D Re-Organization of the B-Cell Genome

The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia

Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs)

Class I PI3K Is Required for HSC Differentiation

Altered Iron Parameters and Hepcidin Levels in a General Population: Lessons from the CHRIS Study

PI3Kδ Inhibition Enhances Sensitivity of Primary High-Risk Childhood B-Cell Acute Lymphoblastic Leukemia Cells to Glucocorticoid Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only